Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW906 in Healthy Subjects and Mild Hypertension
NCT07884461Phase 1Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing GW906 Group with Placebo Group (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events at Month 3. Started Mar 2025; status: completed.
02
Drugs
GW906
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07884461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884461.